European Commission Approves Teizeild to Delay Onset of Type 1 Diabetes
Teizeild (teplizumab) becomes the first disease-modifying therapy approved in the EU to delay progression to stage III type 1 diabetes in eligible adults and children aged eight and above.
Autoimmune Disease | 13/01/2026 | By News Bureau
Novartis Advances Ianalumab Toward Approval for Sjogren's Disease After Phase III Success
Novartis has reported positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjogren's disease.
Autoimmune Disease | 11/08/2025 | By Dineshwori | 132
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy